Karim Lalji

Mr. Lalji has served as Microbion’s CEO since 2015. He brings 25 years of leadership experience in pharmaceutical product marketing and commercial development. He began his career with Merck & Company, where he led the infectious disease new product portfolio from the commercial perspective, with responsibility for products such as INVANZ, CANCIDAS, and CRIXIVAN. After Merck, Mr. Lalji worked at Sepracor, Inc., where he was VP of Business Strategy and New Product Commercialization. He was the primary architect of LUNESTA for the treatment of insomnia. In 2006, Mr. Lalji joined Cardiome Pharma Corp. as Senior VP of Commercial Affairs and an officer of the company. He played a pivotal role in driving Cardiome's US $800 million global development and co-commercialization licensing deal with Merck & Company for vernakalant. Mr. Lalji holds a Science Masters Degree in Health Policy and Management from Harvard University and a BBA from Simon Fraser University in British Columbia.